Tybjergvej 63, 2720 Vanløse, Denmark.
Anticancer Res. 2013 Aug;33(8):3275-8.
We report on a retrospective, consecutive non-randomized group of patients who received bevacizumab plus chemotherapy without bevazicumab maintenance.
Patients with adenocarcinoma subtype of NSCLC and advanced disease received carboplatin and vinorelbine together with bevazicumab for four cycles without bevazicumab maintenance. Overall survival (OS), progression-free survival (PFS), response rate (RR) and toxicity were reviewed.
A total of 30 consecutive patients were included in a period of two years. RR, bleeding, thromboembolic and haematological complications were comparable to those of the literature. Median OS and PFS were 8.8 and 4.5 months for patients with performance status (PS) 0-1, while they were 2.6 and 1.2 months for those with PS 2, p-values being 0.006 and 0.039, respectively.
The effect of maintenance bevazicumab on OS has not yet been established but it has been proven as being favourable on PFS. Our data suggest that patients with PS 2 should not receive this treatment.
我们报告了一组回顾性、连续的非随机分组的患者，他们接受了贝伐珠单抗联合化疗，而没有进行贝伐珠单抗维持治疗。
患有非小细胞肺癌腺癌亚型且处于晚期的患者接受卡铂和长春瑞滨联合贝伐珠单抗治疗，共进行 4 个周期，不进行贝伐珠单抗维持治疗。回顾了总生存期（OS）、无进展生存期（PFS）、缓解率（RR）和毒性。
在两年的时间内，共纳入了 30 例连续患者。RR、出血、血栓栓塞和血液学并发症与文献报道的相似。PS 0-1 患者的中位 OS 和 PFS 分别为 8.8 和 4.5 个月，而 PS 2 患者的 OS 和 PFS 分别为 2.6 和 1.2 个月，p 值分别为 0.006 和 0.039。
维持贝伐珠单抗对 OS 的影响尚未确定，但已被证明对 PFS 有利。我们的数据表明，PS 2 的患者不应接受这种治疗。
